Whitepaper: Disease state primary cells bring verification and validation studies closer to real-world results

Discover how BioIVT’s portfolio of disease state LEUKOMAX® leukopaks and PBMCs can serve as representative starting materials for autologous cell therapy research.

Whether you’re developing a cell or gene therapy, or any of the ancillary equipment or consumables for their manufacture, disease state immune cells can help you control more variables, bringing you closer to real-world results.

In this whitepaper, learn about BioIVT’s safe and ethical disease state immune cell collections, how disease state progressions and treatments affect cellular material and the applications of disease state cells for therapeutic development and verification/validation studies.